| 1. |
- Hörnsten, J, et al.
(författare)
-
Cardiac Implantable Electronic Device Infections; Long-Term Outcome after Extraction and Antibiotic Treatment
- 2021
-
Ingår i: Infectious disease reports. - : MDPI AG. - 2036-7430 .- 2036-7449. ; 13:3, s. 627-635
-
Tidskriftsartikel (refereegranskat)abstract
- Background: The aim of the study was to examine the treatment outcome for patients with cardiovascular implantable electronic device (CIED) infections after extraction. Methods: Patients who underwent CIED extractions due to an infection at Karolinska University Hospital 2006–2015 were analyzed. Results: In total, 165 patients were reviewed, 104 (63%) with pocket infection and 61 (37%) with systemic infection. Of the patients with systemic infection, 34 and 25 patients fulfilled the criteria for definite and possible endocarditis, respectively. Complications after extraction occurred only in one patient. Reimplantation was made after a mean of 9.5 days and performed in 81% of those with pocket infection and 44.3% in systemic infection. Infection with the new device occurred in 4.6%. The mean length of hospital stay for patients with pocket infection was 5.7 days, compared to 38.6 days in systemic infection. One-year mortality was 7.7% and 22.2% in pocket infection and systemic infection, respectively. Patients with Staphylococcus aureus infection had a higher mortality. Conclusions: In this study, the majority of the patients had a pocket CIED infection, with a short hospital stay. Patients with a systemic infection, and S. aureus etiology, had a prolonged hospital stay and a higher mortality.
|
|
| 2. |
- Nygren, D., et al.
(författare)
-
Aortitis caused by Abiotrophia defectiva: Description of two cases
- 2018
-
Ingår i: Infectious Disease Reports. - : MDPI AG. - 2036-7430 .- 2036-7449. ; 10:3, s. 60-63
-
Tidskriftsartikel (refereegranskat)abstract
- Abiotrophia defectiva is a well-known endocarditis pathogen, however it has never been described as a cause of primary aortitis. Here we describe the first published case of thoracic aortitis and an unusual case of aortic graft infection due to A. defectiva, which were both managed conservatively.
|
|
| 3. |
- Harapan, Harapan, et al.
(författare)
-
Willingness to Pay (WTP) for COVID-19 Vaccine Booster Dose and Its Determinants in Indonesia
- 2022
-
Ingår i: Infectious Disease Reports. - : MDPI AG. - 2036-7449. ; 14:6, s. 1017-1032
-
Tidskriftsartikel (refereegranskat)abstract
- Willingness to pay (WTP) for booster doses of coronavirus disease 2019 (COVID-19) vaccines is an under studied research topic. Therefore, the current study aimed to investigate the WTP for the booster doses of COVID-19 vaccines and its predictors in Indonesia using an online survey distributed all over the provinces of this low-middle-income country. The WTP was evaluated using a basic dichotomous contingent valuation approach, and its associated determinants were evaluated using a linear regression model. Out of 2935 responders, 66.2% (1942/2935) were willing to pay for a booster dose of the COVID-19 vaccine. The majority of respondents (63.5%) were willing to pay within a price range of 100,000–500,000 Indonesian rupiah (IDR), i.e., USD 6.71–33.57. Being older than 40 years, having a higher educational level, having a higher income, knowing and understanding that booster doses were important, and having a vaccine status that is certified halal (permissible in Islamic law), were all associated with a higher WTP for the booster dose of COVID-19 vaccines. The study findings imply that the WTP for a booster dose of COVID-19 vaccination in Indonesia is lower compared to acceptance of vaccines provided free of charge. This WTP data can be utilized to develop a pricing scheme for the booster doses of COVID-19 vaccination in the country with potential benefits in other low-income countries. The government may be required to provide subsidies for the herd immunity vaccination process to proceed as anticipated. Furthermore, the public community must be educated on the importance of vaccination as well as the fact that the COVID-19 epidemic is far from being over.
|
|
